Summary: New research suggests that GLP-1 receptor agonists—widely prescribed medications such as Ozempic and Wegovy—may substantially reduce behaviors associated with violence. An analysis of a nationally representative 2025 survey of U.S. adults found that current use of GLP-1 drugs weakened the link between high impulsivity and violent behavior by about 62% and reduced the association between alcohol use and violent conduct by roughly 52%.
The results indicate these metabolic medications could alter neural processes connected to impulse control and reward, producing effects similar to cognitive behavioral therapy (CBT) by increasing the mental distance between an aggressive impulse and a violent act. While promising, the findings are observational and call for longitudinal and experimental research to confirm causality and clarify mechanisms.
Key Facts
- Behavioral Moderation: GLP-1 receptor agonists, commonly used to treat diabetes and obesity, appear to change psychological pathways relevant to violent behavior.
- 62% Reduction in Impulsive-Action Link: In the study, the association between impulsive personality traits and physical violence was 62% weaker among current GLP-1 users compared with former users.
- 52% Weaker Alcohol–Violence Relationship: Current GLP-1 users showed a roughly 52% weaker relationship between alcohol use and violent offenses, though this result was less consistent across sensitivity checks.
- CBT-Like Effect on Brain Function: Researchers propose these drugs may act like CBT by dampening the immediate pathway from sudden impulse to action rather than eliminating impulsivity entirely.
- Study Design and Limits: The analysis used data from a 2025 U.S. survey of 7,521 adults, focusing on 821 people who had ever used a GLP-1 medication; it is cross-sectional and cannot establish cause and effect.
Source: Rutgers University
Overview
Researchers at Rutgers University examined whether GLP-1 receptor agonists (GLP-1 RAs) influence violent criminal behavior by moderating the behavioral pathways that connect impulsivity and alcohol use to aggression. The analysis used a nationally representative 2025 survey of 7,521 U.S. adults, isolating a subgroup of 821 respondents who reported ever using a GLP-1 medication. Among those, 597 were current users and 224 were former users.
Violent behavior was assessed using a validated self-report offending scale that captures actions such as fighting, assault, and robbery. The research team compared current and former GLP-1 users and applied negative binomial regression models with overlap weighting to evaluate whether medication status altered the strength of associations between impulsivity, alcohol consumption, and violent acts in the past year.
Lead author Daniel Semenza, director of research at the New Jersey Gun Violence Research Center and an associate professor at the Rutgers School of Public Health, highlighted the central finding: the well-established link between impulsivity and violent behavior was substantially attenuated among current GLP-1 users compared with those who had stopped using the medication.
Coauthor Christopher Thomas, an assistant professor at Rutgers University–Camden, noted that the pattern of results is consistent with a mechanism where GLP-1 medications weaken the immediate connection from impulse to action, producing an effect similar to CBT. In practical terms, the drugs may provide a brief neural pause that makes it easier to override destructive urges.
Although both impulsivity and alcohol use remained associated with violent behavior overall, the strength of those associations dropped significantly for current GLP-1 users. The interaction between GLP-1 use and impulsivity showed robust support across sensitivity analyses. The alcohol interaction also indicated attenuation but was less consistent across robustness checks, and therefore should be interpreted with more caution.
Key Questions Answered:
A: GLP-1 receptors are present not only in the gut but also in brain regions that regulate reward, dopamine signaling, motivation, and impulse control—areas such as the striatum and prefrontal cortex. By stabilizing signaling in these networks, GLP-1 medications can alter how the brain processes rewards and immediate urges, reducing the intensity of compulsive drives that contribute to harmful behaviors.
A: Cognitive behavioral therapy helps people pause and choose not to act on harmful impulses. The study suggests GLP-1 medications may produce a comparable effect chemically: they do not necessarily change a person’s underlying impulsive traits, but they appear to weaken the direct neurological route from impulse to action, making it easier to resist acting on aggressive urges.
A: No definitive claims can be made yet. This Rutgers analysis is observational and cross-sectional, capturing a snapshot in time. It cannot prove that starting a GLP-1 medication causes a reduction in violent behavior. The authors call for rigorously designed longitudinal and experimental studies to confirm whether GLP-1 treatments reduce violence risk and to unpack the biological and behavioral mechanisms involved.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by editorial staff.
About this research
Author: Patrice Harley
Source: Rutgers University
Contact: Patrice Harley – Rutgers University
Image: The image is credited to Neuroscience News
Original Research: Open access. “GLP-1 receptor agonist use and violent crime among US adults” by Daniel C. Semenza and Christopher Thomas. Criminology. DOI: 10.1111/1745-9125.70058
Abstract
GLP-1 receptor agonist use and violent crime among US adults
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications widely prescribed for diabetes and obesity, have shown emerging effects on substance use, reward processing, and impulse control. This study investigates whether current GLP-1 RA use moderates known behavioral pathways from impulsivity and alcohol use to violent crime.
The analysis used a 2025 nationally representative U.S. survey (n = 7,521; 821 lifetime GLP-1 RA users). Negative binomial regression models with overlap weighting compared current (n = 597) and former (n = 224) users on self-reported violent criminal behavior in the past year.
Although impulsivity and alcohol use were strongly associated with violent criminality overall, those associations were significantly weaker among current GLP-1 RA users (GLP-1 RA × impulsivity incidence rate ratio (IRR) = 0.38, p = 0.002; GLP-1 RA × alcohol use IRR = 0.48, p = 0.023). Robustness checks consistently supported the impulsivity interaction; evidence for the alcohol interaction was less consistent.
These results suggest GLP-1 RAs may attenuate behavioral risk mechanisms linked to aggression, raising new biosocial hypotheses about pharmacological influences on violent criminality. Future longitudinal and experimental research is needed to confirm these findings and test causal pathways.